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The specificity of the veto effect mediated by CTLWeizmann Institute of Science
clones was shown by several studies to be unrelatedRehovot 76100
to their T cell receptor specificity (Claesson, 1987; Sam-Israel
bhara and Miller, 1991, 1994).
The suppression of effector CTL-p directed against
the veto cells is both antigen specific and MHC restricted,Summary
resulting from the unidirectional recognition of the veto
cell by the responding cytotoxic T lymphocytes but notSeveral bone marrow cells and lymphocyte subpopu-
vice versa (Sambhara and Miller, 1991). Furthermore, itlations, known as “veto cells,” were shown to induce
has been shown that this suppression is mediated bytransplantation tolerance across major histocompati-
apoptosis (Sambhara and Miller, 1991; Hiruma et al., 1992).bility antigens. Recently, it has been suggested that
Blocking experiments with anti-CD8 or anti-class Ianti-third party CTLs depleted of alloreactivity are en-
antibodies indicated that the elimination of host antido-dowed with marked veto activity and therefore might
nor CTL-p is induced upon the interaction of CD8 mole-potentially facilitate bone marrow allografting without
cules on the CTL veto cells with the a3 domain of classgraft versus host disease (GVHD). The veto mechanism
I molecules on the host CTL-p’s (Sambhara and Miller,is still obscure. While early studies emphasized the
1991). This finding was also supported by gene transferrole of CD8-mediated apoptosis, more recent evi-
of CD8 cDNA (Sambhara and Miller, 1991) into clonesdence indicates a role for Fas-FasL. In the present
lacking CD8. Another indication that CD8 on the vetostudy we show, by using blocking anti-CD8 antibody,
cells can directly induce apoptosis in effector cells wasby generating CTLs from FasL or perforin mutated
shown by Qi et al. (1996), attaching soluble CD8 mole-mice, and by gene transfer of FasL, that the veto activ-
cules to CD8-negative cells using a hybrid antibody.ity of anti-third party CD81 CTLs is dependent upon
More recently, Asiedu et al. (1999) suggested that cross-the simultaneous expression of both CD8 and FasL.
linking of CD8 on primate bone marrow veto cells by an
antibody led to an increased TGFb production that, inIntroduction
turn, was found to induce apoptosis in the effector cells.
Alternatively, it has been suggested that mouse boneThe establishment of donor-type chimerism under sub-
marrow veto cells can induce apoptosis via Fas-FasLlethal conditioning represents a most desirable goal in
interaction (George et al., 1998). A major obstacle fortransplantation biology, as it is generally associated with
drawing a coherent picture from relevant pieces of infor-durable tolerance toward cells or tissues from the origi-
mation regarding the veto mechanism/s is the diversitynal donor. However, the marked level of host hematopoi-
of veto cell phenotypes used during the past decade.etic and immune cells surviving mild preparatory regi-
In particular, due to the use of different cell types, it ismens represents a difficult barrier for the engraftment of
not clear whether the role reported for CD8-induceddonor cells. Several studies have shown that this challenge
apoptosis is independent of Fas-FasL.
can be successfully addressed in rodents by using large
Very recently, we demonstrated that donor-type CTL
doses of bone marrow cells, adequately depleted of T cells
veto cells could be effectively depleted of alloreactivity
to avoid GVHD (Lapidot et al., 1989; Uharek, 1992; Bachar- against host cells if they are prepared by stimulation
Lustig et al., 1995; Sykes et al., 1997). Alternatively, this against third party stimulators in the absence of exoge-
goal could be achieved by using regular doses of T cell nous IL-2 (Bachar-Lustig et al., 2000). This approach was
depleted marrow in conjunction with one form or another based on the observation that only the activated CTL
of tolerance-inducing cells. In this context, several veto precursors (CTL-p’s) are capable of surviving the IL-2
cells or bone marrow facilitating cells have been de- deprivation in the primary culture. Indeed, preliminary
scribed (Cobbold et al., 1986; Strober et al., 1987; Kikuya results in a fully allogeneic transplantation model sug-
et al., 1988; Lapidot et al., 1990; Tscherning and Claes- gest that such cells can facilitate the induction of donor-
son, 1991; Kiyoshi et al., 1992; Lapidot et al., 1992; Pierce type chimerism in sublethally irradiated recipients, with-
and Watts, 1993a, 1993b; Kaufman et al., 1994). Veto activ- out causing GVHD.
ity was defined in 1980 by Miller as the capacity to specifi- In the present study, we examined the veto activity
cally suppress cytotoxic T cell precursors directed mediated by anti-third party CTLs. As these cells ex-
against antigens of the veto cells themselves but not press both FasL and CD8, it afforded an opportunity to
against third party antigens (Miller, 1980). Interestingly, test the relative role of each of these molecules.
it has been shown that some of the most potent veto
cells are of T cell origin, and, in particular, a very strong Results
veto activity was documented for CD81 CTL lines or
Veto Activity of Anti-Third Party CTLs
To evaluate the veto activity of nonalloreactive anti-third* To whom correspondence should be addressed (e-mail: yair.reisner@
weizmann.ac.il). party CTLs, Balb/c (H-2d) splenocytes were stimulated,
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The dose response curve (Figure 1B) suggests that the
anti-third party CTLs possess a very marked veto activ-
ity, attaining inhibition greater than 80% at a 1:50 veto/
responder cell ratio. Addition of veto cells at 5-fold or
higher concentrations leads to nonspecific elimination
of CTL-p’s, directed at targets not sharing the donor-
type H-2 determinants (data not shown).
The critical time for adding the veto CTLs was found
to be between day 0 and day 2 of the MLR culture
(data not shown). Thereafter, the veto effect is markedly
reduced. Thus, as suggested in the early studies of Miller
et al., it seems that the veto cells inhibit or delete the
responder cells at the precursor level (Miller, 1980). Once
these CTL precursors develop into differentiated CTLs,
the veto cells can no longer exert their effect.
Addition of the veto CTLs in the presence of mono-
clonal antibodies (19/178) directed against CD8a Ly-2.2
allele present on the anti-third party CTLs but not on
the responder cells markedly inhibited the veto effect.
In two experiments, more than 95% inhibition of the veto
effect was recorded at different antibody concentrations
ranging from 40 mg to 10 mg per ml. No inhibition was
found at a concentration of 4 mg or when adding a
nonrelevant antibody such as CD11b (data not shown).
Thus, we confirmed the suggestion of Sambhara and
Miller (1991) that CD8 molecules on the veto cells medi-
ate their inhibitory effect on the responder cells.
The Role of Fas-FasL Apoptosis
Sambhara and Miller (1991) observed that the interac-
tion of CD8 molecules on the veto CTLs with a3 domain
on class I molecules on the CTL-p within the responderFigure 1. Veto Activity of Anti-Third Party CTLs: Evidence for Target
population leads to apoptosis of the latter cells. WeSpecificity
confirmed the role of apoptosis by two approaches. (1)Specific lysis exhibited by responder cells (C3H/Hej) stimulated
against Balb/c (g) or SJL (c) splenocytes (control for nonspecific Addition of the apoptosis inhibitor BD-FmK or of Fas
inhibition), in the presence of different concentrations of cells from antagonist (Suda and Nagata, 1994) (a soluble fusion
a Balb/c anti-third party (C57BL/6) CTL line. (A) shows average 6 protein that consists of the extracellular region of Fas
standard deviation of 17 different experiments. (B) shows a repre-
and Fc region of human IgG1) was found to inhibit thesentative experiment.
veto effect of anti-third party CTLs (Figure 2). (2) Addition
of anti-third party CTLs of Balb/c (H-2d) origin, to MLR
of TCR transgenic C57BL/6 responders bearing the 2Cin the absence of IL-2, against irradiated (20 Gy) C57BL/6
(H-2b, third party) splenocytes in MLR culture for 4 days. TCR directed against H-2d (stained by the clonotypic
antibody 1B2), led to marked specific deletion of theOn the fifth day of the cell culture, rhIL-2 was added
and the cells were kept for additional 6 days. After cul- transgenic responders upon stimulation against Balb/c
stimulators (Figure 3). Thus, following 5 days MLR theture, these cells were harvested and tested for their veto
activity, upon addition to bulk MLR cultures of C3H/ precursors of CD811B21 T cells were reduced from
23.6% to 9.2% upon the addition of anti-third party CTLsHeJ (H-2k) responder cells (host type) stimulated against
irradiated splenocytes from Balb/c (H-2d donor type) or from Balb/c origin. In contrast, the percentage of
CD811B21 T cells found following addition of CTLs fromfrom SJL (nonrelevant control, H-2s). The inhibition of
killing activity exerted by the veto cells on the responder SJL origin was not significantly reduced (23.7%).
The inhibition of the veto effect by Fas-Fc (Figurecells was determined by 51Cr- release assay, after 6 days
in culture. 2) indicated that Fas-FasL-mediated apoptosis is likely
involved in the veto effect of anti-third party CTLs. Con-As can be seen in Figures 1A (17 different experi-
ments) and 1B (one representative experiment), addition sidering that two distinct major apoptosis mechanisms,
namely perforin-mediated or Fas-FasL-mediated apo-of cells generated in a Balb/c CTL line directed against
a third party inhibited the killing activity of the responder ptosis, have been described (Berke, 1997), we prepared
two different anti-third party CTL lines from splenocytescells (C3H/HeJ) that were cocultured with Balb/c stimu-
lators. In contrast, the addition of cells from the same of Fas-L-deficient strain (C3H/HeJ-gld, H-2k) or from
splenocytes of perforin-deficient mice (PO, H-2b). C3H/CTL line to responder cells (C3H/HeJ) that were stimu-
lated against SJL splenocytes only slightly affected the HeJ-gld or PO splenocytes were stimulated against irra-
diated C57BL/6 (H-2b) or DBA/1(H-2q) splenocytes, re-responder’s killing activity. The specificity revealed by
these results suggests that the nonalloreactive CTLs spectively, as described for wild-type splenocytes (cul-
ture of 10 days, without exogenous hrIL-2 during thedirected against a third party indeed exhibit veto activity.
FasL and CD8 Are Both Critical for Veto CTLs
509
than that exhibited by wild-type C57BL/6 CTLs (range 5
61%–68%).
Finally, further evidence to the role of FasL in the veto
effect was afforded by gene transfer experiments in
which gld-anti-third party CTLs were transfected with
FasL, using a retroviral vector.
To verify the functionality of FasL on the transfected
CTLs, we measured initially their capacity to kill Fas-
positive Jurkat cells (Table 2, footnote). When tested
in the appropriate MLR cultures, in two independent
experiments, FasL transfected CTLs exhibited marked
veto activity compared to EGFP-transfected CTLs from
gld mice. The specificity of the veto activity was verified
by testing the FasL transfected cells in MLR against SJL
Figure 2. Veto Activity of Anti-Third Party CTLs: The Role of FasL (Table 2). Using a similar approach, we also investigated
Inhibitors the role of Fas. As can be seen in Figure 4, the addition
CTL activity was measured after 6 days of MLR culture consisting of Balb/c anti-third party CTLs to MLR culture in which
of C3H/HeJ responders and Balb/c stimulators in the absence (G) Fas-deficient C3H.MRL-lpr splenocytes were stimulated
or presence (C) of Balb/c anti-C57BL/6 (third party) veto CTLs. The
against Balb/c failed to inhibit the primary CTLs. In con-inhibitory activity of the veto cells was tested in the absence (a) and
trast, marked veto activity was exhibited by these cellspresence of Fas-Fc fusion protein (FasL antagonist) (b) or BD-fmk
when added to primary MLR cultures of wild-type C3H/(c). CTL activity was evaluated as follows: % specific lysis 5 100 3
((experimental release 2 spontaneous release)/(maximum release 2 HeJ responders.
spontaneous release)). The standard deviation (SD) of replicate val- FACS analysis of Fas during a typical MLR of 2C sple-
ues was consistently less than 10% of the mean. The figure shows nocytes against Balb/c stimulators revealed that as ex-
average 6 standard deviation of three experiments. pected Fas expression on CD81 1B21 T cells is en-
hanced at 48 hr. Addition of Balb/c anti-C3H/HeJ but
not SJL anti-C3H/HeJ CTLs led to a marked deletion of
first 4 days). The use of veto cells of gld-C3H/HeJ (H-2k) the Fas1 activated CD8 T cells (Figure 5). These results
and PO (H-2b) origin necessitated changes in the design illustrate the potent veto activity and the remarkable
of our MLR responders and stimulators. Thus, the gld specificity by which the anti-third party veto CTLs ex-
mutant anti-third party CTLs were added to bulk MLR in pressing FasL (Suda et al., 1995; Li et al., 1998) are
which Balb/c responders were stimulated against C3H/ capable of selectively killing Fas1 T cells aimed against
HeJ splenocytes. The PO knockout anti-third party CTLs their H-2 antigens.
were added to bulk MLR in which C3H/HeJ responders Altogether, these results suggest that the veto effect
were stimulated against PO or SJL splenocytes. of anti-third party CTLs is likely mediated by engaging
As can be see in Table 1, the anti-third party CTLs the effector CTL-p with both CD8 and FasL on the veto
originating from C3H/HeJ-gld lacked appreciable veto CTLs. These stimuli might be provided either by CD81
activity. In four out of five experiments, no veto activity CTLs coexpressing CD8 and FasL or by engaging two
could be detected when testing anti-third party CTLs different cells positive either for CD8 alone or for FasL
generated from C3H-gld mice, and in one experiment alone. Although it has been shown before by using CTL
the added CTLs exhibited a marginal 11% inhibition. In clones that CD8 CTLs are responsible for the marked
contrast, the two experiments with CTLs originating veto activity found in CTL lines (Claesson, 1984; Fink et
from perforin-deficient mice did exhibit marked veto ac- al., 1984a, 1984b; Claesson and Miller, 1989), we further
addressed this question by purifying CD81 T cells fromtivity (range 5 96% to 100%), which was even higher
Figure 3. Specific Deletion of Responder CTL-p Directed against the H-2 of the Veto Cells
Splenocytes from 2c transgenic mice (H-2b) bearing transgene TCR specific against H-2d (1B21) were stimulated in MLR against Balb/c
splenocytes (H-2d). The frequency of 1B21 CD8 T cells before (A) and after addition to the MLR culture of Balb/c anti-C3H/HeJ (B) or SJL
anti-C3H/HeJ (C) CTLs was determined by FACS, 5 days after initiation of the MLR.
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Table 1. Veto Activity of Anti-Third Party CTLs Generated from Different Strains of Mice
Anti-Third Party CTL’s (Origin) CTL Activitya (% Specific Lysis) Veto Activityb (% CTL Inhibition)
Experiment Number Experiment Number
1 2 3 4 5 1 2 3 4 5
C3H-gld 2 37 32 29 47 40
1 37 34 34 69 55 0 0 11 0 0
C3H/HeJ 2 34 26
1 22 14 36 47
C57BL/6-Po 2 15 24
1 0 1 100 96
C57BL/6 2 31 40
1 12 13 61 68
a CTL activity was evaluated as follows: % specific lysis 5 100 3 ((experimental release 2 spontaneous release)/(maximum release 2
spontaneous release)). The standard deviation (SD) of replicate values was consistently less than 10% of the mean.
b Anti-third party CTLs were added to the appropriate MLR at a 1:50 effector/veto cell ratio. Veto activity of tested cells was evaluated by the
inhibition of CTL generation in the MLR to which they were added.
our anti-third party CTL lines . The purified CD81 CTLs mediate this facilitating effect (Rachamim et al., 1998).
fully retained their veto activity (data not shown). The “megadose” concept was also shown recently to
Therefore, considering that FasL-deficient CTLs of gld be useful for tolerance induction in sublethally irradiated
background fail to exhibit veto activity and that the veto mice, so as to effectively overcome the marked resis-
activity is uniformly blocked by anti-CD8 antibody, the tance presented by the large number of lymphocytes
veto activity exhibited by purified CD81 anti-third party surviving the sublethal conditioning (Bachar-Lustig et
CTLs clearly demonstrates that coexpression of CD8 al., 1995; Sykes et al., 1997). Furthermore, allogeneic
and FasL is a prerequisite for the veto activity of CD81 chimera generated by transplantation of large doses of
CTLs. Sca-11Lin2 cells permanently accept allogeneic donor-
type skin grafts (Bachar-Lustig et al., 1999). However,
the numbers required to attain this desirable goal mayDiscussion
not be easily collected from human donors. Nonalloreac-
tive (host 3 donor) F1 purified T cells that are nonallore-Early studies in murine models (Lapidot et al., 1988, 1989;
active by virtue of their genetic composition (LapidotUharek, 1992; Reisner and Martelli, 1995) and more re-
et al., 1990, 1992) or T cells purified from establishedcent clinical data in heavily pretreated leukemia patients
chimeric mice (Faktorowich et al., 1993) were shown to(Aversa et al., 1994, 1998; Reisner et al., 1999) have shown
enhance engraftment of T cell depleted BM allografts.that escalation of hematopoietic progenitor cells can
More recently, the former cells were shown to synergizeovercome major genetic barriers and enable rapid and
with murine Sca-11Lin2 cells so as to reduce the minimaldurable engraftment of haploidentical 3-loci mismatched
number required to achieve induction of substantialtransplants without GVHD. In vitro studies suggest that
veto cells within the CD34 progenitors population likely mixed chimerism in the sublethal mouse model (Bachar-
Table 2. Reversal of Veto Activity in FasL-Deficient CTLs by Gene Transfer of FasLa
Anti-Third Party CTL’s Origin CTL Activityb (% Specific Lysis) Veto activityc (% CTL Inhibition)
Experiments Experiments
1 2 1 2
C3H-gld 2 24 19
1 26 16 0 15.8
EGFP transfected gld 2 42 ND
1 42 ND 0
FasL transfected glda 2 27 79
1 0 37 100 53.2
FasL transfected gld (SJL control)d 2 27 38
1 34 31 0 29
a To verify the functionality of FasL on the transfected CTLs, we measured initially their capacity to kill Fas-positive Jurkat cells. In this
preliminary experiment, FACS analysis of EGFP-positive cells revealed 8.3 and 29.7 percent positive cells within the CTLs transfected with
both FasL and EGFP or with EGFP alone, respectively. Direct cytotoxicity of Fas-positive Jurkat target cells by the FasL transfected cells
showed significantly higher cytotoxic index (40%) compared to the level exhibited by CTLs transfected with EGFP alone (17%).
b CTL activity was evaluated as follows: % specific lysis 5 100 3 ((experimental release 2 spontaneous release)/(maximum release 2
spontaneous release)). The standard deviation (SD) of replicate values was consistently less than 10% of the mean.
c Veto activity of tested cells was evaluated by their capacity to inhibit alloreactive CTL in the MLR to which they were added at 1:50 effector/
veto cell ratio.
d Anti-third party CTLs generated from C3H-gld background transfected with FasL were tested for their veto activity in a control MLR culture
of Balb anti-SJL.
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deletion or anergy induction. Once such antihost CTLs
are generated, it is very difficult to suppress their allore-
activity in vivo.
An alternative approach is based on earlier studies,
which showed that CD81 CTL clones possess extremely
high veto activity (Claesson, 1984, 1987; Fink et al., 1984a;
Rammensee et al., 1984; Sambhara and Miller, 1991;
Jameson et al., 1993; Yanagie et al., 1993; Zhang et al.,
1994). Thus, very recently Bachar et al. (2000) suggested
that donor anti-third party CTLs can be depleted of anti-
host alloreactivity if exogenous IL-2 is not provided dur-
ing the initial 5 days of the bulk culture with the stimulator
cells.
In the present study, we further documented, in vitro,
the marked potent veto activity of such anti-third party
CTLs. Using anti-CD8 mAb against the allelic form ex-
pressed on the veto cells, we confirmed the previousFigure 4. Veto Activity of Anti-Third Party CTLs: The Role of Fas
observation that these molecules are likely involved inResponder T cells of Fas-deficient C3H.MRL-lpr background were
compared to wild-type C3H/HeJ responder cells for their sensitivity generating the veto effect. In addition, we further con-
to the veto effect induced by Balb/c anti-C57BL/6 CTLs. MLR cul- firmed and extended the early indications that CTL veto
tures for veto determination consisted of C3H.MRL-lpr anti-Balb/c cells lead to apoptosis of CTL-p directed against their
(G) or C3H.MRL-lpr anti-SJL (C) (as a control for nonspecific inhibi-
antigens. Thus, 2C TCR transgenic effector cells bearingtion). Veto activity of tested cells was evaluated by their capacity
a transgene directed against class I H-2d were deletedto inhibit CTL generation in the MLR to which they were added. The
upon incubation in MLR with veto CTLs of H-2d origin. Byfigure shows average 6 standard deviation of four experiments.
using anti-third party nonalloreactive CTLs, generated
from spleen cells of different mutant mice, we now con-
Lustig et al., 1999). In humans, nonalloreactive T cells clude that the veto activity of these cells is mediated
can be generated by purging interleukin-2 receptor-pos- by apoptosis via the Fas-FasL system and not by the
itive (CD251) MLR reactive T cells (Cavazzana Calvo et perforin mechanism. Moreover, our results suggest that
al., 1994; Korb et al., 1999) or by anergy induction upon simultaneous expression of both CD8 and FasL on the
incubation with CTLA-4 (Gribben et al., 1996; Woodward CD81 CTLs and the expression of Fas on the effector
et al., 1996). However, these approaches, which make CTL-p are prerequisites for the veto activity.
use of T cell stimulation with the very antigens against These results contradict those documented recently
which tolerance is desired, might involve some risk for for peptide-induced paralysis of CD81 cytotoxic effector
T cells. Using mixing experiments with CTL populationsgenerating committed CTLs, if any of the CTL-p escape
Figure 5. Deletion of Fas-Positive Effector T
Cells by Anti-Third Party Veto CTLs
Splenocytes from 2c transgenic mice (H-2b)
bearing transgene TCR specific against H-2d
were stimulated in MLR against Balb/c spleno-
cytes (H-2d). Expression of Fas on CD8 trans-
genic (1B21) T cells was analyzed by FACS
before MLR (A) and at 48 hr (B). Deletion of
Fas11B21 CD8 T cells following addition to the
MLR culture of Balb/c anti-C3H/HeJ (C) or
SJL anti-C3H/HeJ (D) CTLs was determined
at 48 hr after initiation of the MLR.
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of different peptide specificities restricted to the same patients. If successful, it may also lead to safe mis-
MHC class I, a veto-like mechanism that was shown to matched hematopoietic transplants in patients for whom
be independent of Fas/FasL interactions and of apopto- the risk of supralethal radio-chemotherapy is not justi-
sis altogether was documented (Bergenthal et al., 1998). fied, such as patients with thalassemia, sickle cell ane-
However, this veto-like effect, which was exhibited in mia, and several enzyme deficiencies. Furthermore, in-
the context of in vivo primed CTLs, is not operative in duction of substantial durable chimerism could be used
our system in which the veto effect is limited to primary to induce tolerance toward subsequent solid organ
alloactivation of CTL-p, and is incapable of eliminating transplants from the original stem cell donor or as a
primed CTLs. prelude for adoptive cell therapy in cancer patients.
Sambhara and Miller (1991) observed in their early
Experimental Proceduresstudy that the CD8 on the veto cells mediate the apopto-
sis of the effector cells, and they suggested that CD8
Animalsmay induce apoptosis by some form of signal transduc-
Mice used were females 6–12 weeks old. BALB/c and C57BL/6
tion upon binding to a3 domain of class I on the effector were obtained from the Weizmann Institute Animal Center (Rehovot,
cells. However, our present finding that CTLs from FasL Israel). C3H/HeJ, C3H/HeJ-gld, and C3H.MRL-lpr were obtained
mutated mice that express normal levels of CD8 com- from the Roscoe B. Jackson Memorial Laboratory (Bar Harbor, ME).
A breeding pair of Transgenic (Tg) H-2b mice expressing the TCRpletely lose their veto activity, and, moreover, our finding
from the CTL clone 2C with specificity for H-2Ld was kindly providedthat the veto activity of these CTLs can be reversed by
by Janko Nikolic-Zugic (Sloan-Kettering, NY). Progeny of these Tggene transfer of FasL, demonstrates that the CD8 on
mice and Perforin-knockout (PO, H-2b) mice were bred at the Weiz-
these cells is functional and can participate in apoptosis mann Institute Animal Breeding Center (Rehovot, Israel). All mice
induction once FasL is reinstated on the cell surface. were kept in small cages (five animals in each cage) and fed sterile
Therefore, we conclude in contrast to Sambhara and food and acid water containing cyprofloxacin (20 mg/ml).
Miller that CD8 by itself cannot trigger apoptosis. More
Preparation of Nonalloreactive Donor Anti-Third Party CTLslikely, it is possible that CD8 induces in the effector T
Splenocytes of Balb/c mice (donor responders) were harvested, andcells susceptibility to Fas-FasL apoptosis.
single cell suspensions were prepared. The cell suspensions wereThe demonstration that both CD8 and FasL are essen-
treated with Tris-buffered ammonium chloride to remove red blood
tial for the veto activity might indicate possible synergy cells, and the isolated mononuclear cells (2 3 106/ml) were stimu-
between the two molecules. However, preliminary re- lated with irradiated (20 Gy) C57BL/6 (third party stimulators) spleno-
sults titering anti-CD8 and FasFc against each other cytes (2 3 106/ml). Responders and stimulators were cultured for
10 days in a complete tissue culture medium (CTCM) at 378C in aindicate lack of such synergism. Further studies will
5% CO2/air incubator. Beginning at day 5 after seeding, human rIL-2define whether the induction of susceptibility to FasL
(20U/ml, Eurocetus, Milan, Italy) was added every day to the mixedby CD8 could be brought about by some form of signal
lymphocyte reaction culture, and on day 7 of the culture the medium
transduction affecting the level of expression of FasL was replaced by a fresh one. At day 10, the MLR cultures were
on the veto cells or the level of regulatory molecules harvested, fractionated on Ficol-Paque plus (Amersham Pharmacia
such as FLIP (Irmler et al., 1997) in the effector cells. Biotech AB, Sweden), analyzed by FACS for their CD8 level, and
added to the MLR cultures at different cell ratios, as described inAlternately, it might be mediated simply via the extra
the Results.affinity contributed by the CD8-MHC interaction. This
additional affinity might be required to allow a produc-
Generation of Purified Anti-Third Party CD81CTL Linestive cell contact between the effector cell and the veto
Anti-third party CTL lines were prepared as described above for 6
cell so as to allow Fas-FasL apoptosis to be triggered. days and fractionated on Ficoll, and the lymphoid fraction was then
Indeed, there are several examples in which CD8 was subjected to positive selection of CD81 cells using magnetically
shown to serve as an accessory recognition molecule labeled anti-CD8 antibodies and a magnetic cell sorting (MACS)
system (Miltenyi Biotec, Bergisch Gladbach Germany).providing the extra affinity required in immune recogni-
tion processes. For example, its synergy with the T cell
MLR Cultures and Cytotoxicity Assayreceptor was shown, by using CD8 transgenic mice, to
Spleen cells of C3H/HeJ mice (responders) were harvested, andplay an important role in defining self versus non-self
single cell suspensions were prepared as described above. The cells
thresholds in thymic recognition (Robey et al., 1992) or (2 3 106/ml) were then stimulated with irradiated (20 Gy) Balb/c spleno-
in defining peripheral tolerance (Auphan et al., 1992). cytes (2 3 106/ml) or with 2 3 106/ml irradiated (20 Gy) SJL spleno-
Recently, several types of veto cells bearing different cytes. Four to six replicates per group were cultured in 96-well
U-bottomed plates in 0.2 ml CTCM for 6 days at 378C (5% CO2phenotypes were shown to exert their veto activity via
atmosphere). ConA blasts generated from SJL or Balb/c spleen cellsthe Fas-FasL system (George et al., 1998; Green, 1999;
(2 days in the presence of 2 mg ConA/2 3 106 cells/ml) were labeledRich and Green, 1999), but it is not clear whether these
with 51Cr (NEN, Boston MA). Cell-mediated lysis assay was performedcells require CD8. Clearly, other adherence molecules
using variable numbers of MLR effector cells and 5 3 103 target
could replace CD8 and afford the critical added affinity, cells in 96-well V-bottomed plates. 51Cr release was measured after
which might be required to bring together Fas and FasL a 4 hr incubation at 378C. Results are expressed as a specific lysis
on the effector and the veto cells, respectively. calculated as follows: %specific lysis 5 100 3 ((experimental release 2
spontaneous release)/(maximum release 2 spontaneous release)).In the future, alternative approaches to generating
The standard deviation (SD) of replicate values was consistentlynonalloreactive anti-third party CTLs could be based on
less than 10% of the mean.gene transfer of FasL in conjunction with CD8, into a
variety of antigen-presenting cells or any other cell, de-
Veto Activity of Anti-Third Party CTLs
pending on the nature of antigens against which toler- To determine whether mouse nonalloreactive donor anti-third party
ance induction is desired. Such cells, similarly to our CTLs possess veto activity, spleen cells from C3H/HeJ mice (2 3
anti-third party CTLs, could help reduce the effective 106/ml) were incubated for 6 days with irradiated (20 Gy, 2 3 106/ml)
Balb/c or SJL spleen cells. Nonalloreactive Balb/c anti-C57BL/6 CTLsCD34 megadose requirements in mismatched leukemia
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were added to the MLC at a 1:100, 1:50, and 1:10 veto:responder References
cell ratio. The killing activity of the responder CTL-p was determined
by a 51Cr-release assay. Asiedu, C., Meng, Y., Wang, W., Huang, Z., Contreras, J., George,
J.F., and Thomas, J.M. (1999). Immunoregulatory role of CD8a in
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